Zelminemab

泽米奈单抗

Report date: 2024/02/05 20:04:22

Base Information

Drug NameZelminemab
Drug Alias NameAMG-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPituitary adenylate cyclase-activating polypeptide type I receptor antagonists
TargetsPituitary adenylate cyclase-activating polypeptide type I receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgAmgen Inc
Active IndicationsN/A
Inactive IndicationsMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A